We have recently shown that a short course of high-dose interleukin-2 (IL-2) can markedly inhibit the graft-versus-host disease (GVHD)-promoting activity of donor CD4' T cells. The difficulty in dissociating GVHD-promoting from graftversus-leukemia (GVL) effects of alloreactive donor T cells currently prevents clinical bone marrow transplantation (BMT) from fulfilling its full potential. To test the capacity of IL-2 treatment t o promote such a dissociation, we have developed a new murine transplantable acute myelogenous leukemia model using a class II major histocompatibility complex-positive BALB/c Moloney murine leukemia virusinduced promonocytic leukemia, 2B-4-2. BALBlc mice receiving 2.5 x lo5 28-4-2 cells intravenously 1 week before irradiation and syngeneic BMT died from leukemia within 2 t o 4 weeks after BMT. Administration of syngeneic spleen cells andlor a 2.5-day course of IL-2 treatment alone did not inhibit leukemic mortality. In contrast, administration of non-ESPITE MAJOR ADVANCES in immunosuppressive therapy and supportive care, bone marrow transplantation (BMT) has yet to realize its full potential for the treatment of leukemia. A major obstacle to long-term success of BMT is graft-versus-host disease (GVHD), which can most reliably be prevented by removing T cells from the marrow. However, T-cell depletion has unfortunately been associated with increased rates of engraftment failure' and increased relapse rates for several types of leukemia.2,3 When HLA nongenotypically identical unrelated donor transplants have been performed, increased GVHD has been at least partially offset by decreased leukemic relapse rates.4 Similar differences have been observed when single HLA antigen-mismatched transplants have been compared with HLA-identical transplant^.^.^ These results suggest that graft-versus-leukemia effects might be even greater if BMT could be performed in the setting of wider HLA mismatches. However, the full potential of this GVL effect cannot be exploited unless severe GVHD can, at the same time, be avoided.
ESPITE MAJOR ADVANCES in immunosuppressive
therapy and supportive care, bone marrow transplantation (BMT) has yet to realize its full potential for the treatment of leukemia. A major obstacle to long-term success of BMT is graft-versus-host disease (GVHD), which can most reliably be prevented by removing T cells from the marrow. However, T-cell depletion has unfortunately been associated with increased rates of engraftment failure' and increased relapse rates for several types of leukemia.2,3 When HLA nongenotypically identical unrelated donor transplants have been performed, increased GVHD has been at least partially offset by decreased leukemic relapse rates.4 Similar differences have been observed when single HLA antigen-mismatched transplants have been compared with HLA-identical transplant^.^.^ These results suggest that graft-versus-leukemia effects might be even greater if BMT could be performed in the setting of wider HLA mismatches. However, the full potential of this GVL effect cannot be exploited unless severe GVHD can, at the same time, be avoided.
We have recently developed a murine model that appears to preserve the beneficial GVL and engraftment-promoting effects of allogeneic T cells while inhibiting GVHD across complete major histocompatability complex (MHC) disparities."'" Administration of a high dose of interleukin-2 (IL-2) for 2.5 days beginning on the day of BMT protects against GVHD mortality in completely MHC-mismatched murine strain combinations, especially when T-cell-depleted (TCD) host-type bone marrow cells (BMC) are coadministered.','' Alloengraftment is not significantly inhibited by IL-2 in this' or other more sensitive models evaluating engraftment." Remarkably, the GVL effect of donor T cells against a hosttype T-cell leukemidlymphoma, EL4, was completely preserved in IL-2-treated mice.' More recently, we evaluated the role of CD4+ and CD8' T cells in producing GVHD and GVL effects in this model. Results of these studies showed that CD4 ' T cells are critical in producing lethal acute GVHD in this (A/J --t B10)" and many other fully MHC plus multiple minor-mismatched strain combinations,13 but that they do not participate in the GVL effect against EL4. This GVL effect is mediated by CD8' T cells in a CD4-independent fashion." These observations provided an explanation for the ability of IL-2 treatment to inhibit GVHD without inhibiting GVL effects against EL4 since CD4-mediated GVHD but not CD8-mediated GVL or GVHD was inhibited by IL-2.'2. '3 The observation that CD4 activity is inhibited by IL-2 treatment suggested that GVL effects against other leukemias, particularly those that express class I1 MHC antigens, might be inhibited by IL-2 treatment. However, other studies suggested that only certain CD4 activities were inhibited by IL-2 treatment, whereas other CD4 functions were preserved." It was important to determine the possible effect of IL-2 treatment on GVL directed against a class 11-positive leukemia, because many human B-cell and myeloid leukemias are class 11-positive. Therefore, we have developed a new murine acute myelogenous leukemia model in BALBk mice in which to evaluate the effect of IL-2. We show that GVL effects of CD4' in addition to CD8+ allogeneic T cells
IL-2 SEPARATES CD4 GVL AND GVHD 2561
against this tumor are fully preserved in IL-2-treated mice in which CD4-dependent GVHD is inhibited by treatment with IL-2.
MATERIALS AND METHODS

Animals.
Female C57BL/10 (B10, H-2b, KbIbDb) and BALBk (H-2d, KdIdDd) mice were purchased from the Frederick Cancer Research Facility, Frederick, MD. Animals were housed in sterilized microisolator cages as described.'
BMT. BMT was performed as previously described' with modifications described below. Recipient mice, aged 9 to 12 weeks, were irradiated (8-Gy whole body irradiation [WBI], I3'Cs source, 1.1 Gylmin) and reconstituted with BMC and spleen cells prepared as described? Host-type (BALBlc) BMC and allogeneic B10 BMC were TCD using rat antimouse CD4 IgGZb monoclonal antibody (MoAb) GK1.5I4 plus rat antimouse CD8 (Ly2.2-specific) IgGlb MoAb 2.4315 and rabbit C, as previously described.' One milliliter of diluted antibody and C was used for 5 X 10' BMC. Because previous studies showed that TCD host-type BMC enhanced the protective effect of IL-2 without impairing alloengraftment,' we coadministered 5 X lo6 TCD host-type BMC in all experiments in which allogeneic CD4+ cells were given. For depletion of CD4+ and/or CD8+ spleen cells, 1 mL of diluted antibody and C was used for lo7 splenocytes. The inocula used in each experiment are described in the Results section and figure legends. Animals in each group were randomized into various cages as previously described,' and survival was monitored daily for 100 days.
2B-4-2 leukemia. 2B-4-2 is a tumor cell line derived in a pristane-primed BALBlc mouse that received an intravenous (IV) injection of Maloney Murine leukemia virus (M-MuLV).'~ The cell line was kindly provided to us by Dr Linda Wolff (National Cancer Institute, Bethesda, MD). The cells were injected intraperitoneally to BALBk mice, and ascites was produced. This ascites was pooled and frozen, and a fresh vial was thawed for use in each experiment. The thawed 2B-4-2 cells were expanded in culture for 1 to 2 weeks in RPM1 supplemented with 10% fetal calf serum, 100 UlmL penicillin, 100 pg/mL streptomycin, 2 mmoVL glutamine, 1 mmoVL sodium pyruvate, 0.09 mmoVL nonessential amino acids, and 0.01 mol/L HEPES buffer. 2B-4-2 cells were administered intravenously 1 week before irradiation and BMT.
In some experiments, carcasses of animals that succumbed were saved in 10% formalin. After completion of the survival study, pathologic examination was performed by an individual who was unaware of the experimental group to which the animals belonged. Gross abnormalities were recorded, and the only abnormality that appeared to be specific for leukemic mice was marked splenomegaly. The specificity of this finding for the presence of leukemia was quite high, as a spleen was determined to be clearly large in only 1 of 17 autopsies (5.9%) in which animals had not received 2B-4-2 cells. Slight or questionable splenomegaly was observed in an additional 2 of 17 animals not receiving 2B-4-2, and animals with this appearance are not reported below as showing splenomegaly.
IL-2 administration. Fifty thousand Cetus Units of recombinant human IL-2, generously provided by Cetus Corp (Emeryville, CA), were injected intraperitoneally as described.' IL-2 was administered 1 to 3 hours before BMT, and then approximately every 12 hours thereafter for a total of 5 doses.
MoAbs and $ow cytometry (FCM). 
RESULTS
Characteristics of transplanted 28-4-2 leukemia. 2B-4-2 is a tumor cell line derived from a pristane-primed BALBJc mouse that received an IV injection of M-MuLV.'~ Previous characterization of these tumors led to their categorization as promonocytic cells based on morphology, cell surface markers, and enzyme-staining characteristics.I6 Similar to previously reported results,I6 our own FCM analyses showed these cells to be Thyl-negative, surface IgM-negative, Macl-positive, class I MHC-positive, and class I1 MHCpositive. They did not express the granulocyte marker Gr-l (data not shown). After thawing and expanding 2B-4-2 cells in vitro for 1 week, various cell numbers were transferred intravenously to BALBJc recipients. As shown in Table 1 , the speed of mortality was a function of cell dose, and 5,000 2B-4-2 cells were sufficient to kill all recipients. One recipient of 5 X lo6 cells was sacrificed on day 14, and its marrow, For personal use only. on November 11, 2017. by guest www.bloodjournal.org From Abbreviation: ND, not determined.
* 26-42 cells were administered intravenously on day 0.
t Number of days animals survived after 28-4-2 administration is shown. On day 7, animals received 8-Gy WBI, followed by IV administration of 5 x lo6 BALB/c BMC. These animals were evaluated in a separate experiment from that in which the Untreated group was tested.
spleen, and blood cultured in vitro. Leukemia cells grew from all three of these tissues.
We next wished to determine which dose of leukemia cells, if any, would cause mortality in lethally irradiated mice bearing established tumor before the time of irradiation. Various doses of 2B-4-2 cells were administered intravenously to BALBk mice, which received lethal irradiation (8 Gy) plus syngeneic BMT 1 week later. As shown in Table  1 Because it was well within the dose range that was lethal for all animals receiving irradiation and BMT, we selected a dose range of 2.5 X lo5 to 7.5 X l@ 2B-4-2 cells for IV administration 1 week before irradiation and BMT in all subsequent experiments. To directly evaluate the cytoreductive capacity of 8-Gy WBI, we compared mortality in animals receiving 2.5 X 10' 2B-4-2 cells with no further treatment, with that of animals receiving similar inocula, followed by 8-Gy WBUsyngeneic BMT 1 week later. As is shown in Fig 1, irradiation followed by rescue with syngeneic BMT led to a small, but statistically significant, prolongation of survival. Similar results were obtained in a repeat experiment. Thus, our model resembled advanced acute leukemia, in which irradiation followed by autologous BMT might be expected to produce only modest prolongation of survival.
In both of these experiments, complete blood counts were performed at 8, 14, and, when available, 21 days post-BMT. In most 2B-4-2-treated BMT recipients, the pattern of hematopoietic recovery was identical to that of BMT controls, showing reduced WBC and platelet counts on day 8, and recovery to normal levels by day 14. However, on day 14, one of four 2B-4-2 recipients showed a markedly elevated SYKES ET AL WBC count (54.7 X I06/mL) associated with a slightly reduced platelet count. Only one 2B-4-2 recipient was analyzed on day 21, and it also showed a markedly elevated WBC count (42.9 X 1O6/mL) and a slightly reduced platelet count compared with simultaneous BMT controls. At autopsy, animals showed varying degrees of splenic enlargement.
Luck of antileukemic effect of IL-2 given with syngeneic marrow. We have recently shown that a short course of high-dose IL-2 can markedly inhibit GVHD in a variety of strain combinations involving a full MHC mismatch, including B10 -+ BALB/c. 13 To determine whether such a course of IL-2 would, on its own, mediate an antileukemic effect against 2B-4-2, we compared leukemic mortality in control and IL-2-treated BALB/c mice that had received 7.5 X lo5 2B-4-2 cells 1 week before lethal WBI and rescue with TCD syngeneic BMC. As shown in Fig 2, a 2 .5-day course of human recombinant It-2, 50,000 U per dose, had no effect on leukemic mortality when given with TCD syngeneic BMC alone. Similar results were obtained in a repeat experiment. Autopsies showed marked splenic enlargement in most animals (14/15) in both groups, with no apparent effect of IL-2 treatment.
GVL effect of allogeneic lymphocytes.
To determine whether or not allogeneic lymphocytes could mediate a GVL effect, we also evaluated the effect of administering fully MHC (plus multiple minor)-mismatched B 10 BM and spleen cells in the experiment shown in Fig 2. We have previously shown that IL-2 can inhibit GVHD mortality in this B 10 -+ BALB/c strain combination,13 so IL-2 was given to recipients of these allogeneic inocula to minimize GVHD. As shown in tumor showed 100% survival. Animals receiving similar inocula, but that had received 2B-4-2 cells one week before irradiation and BMT, showed 100% mortality from leukemia by day 32 (Fig 2) . However, this represented a significant delay in leukemic mortality compared with control IL-2-treated recipients of syngeneic BMC alone, which all died by day 17 ( P < .005), indicating that allogeneic cells mediated a GVL effect in IL-2-treated mice. Similar results were obtained in a repeat experiment. In contrast with autopsies performed on control leukemic mice, those performed on 18 carcasses from leukemic recipients of allogeneic B 10 spleen cells did not show marked splenic enlargement. Histologic analysis also showed a reduction in leukemic infiltrates in recipients of allogeneic inocula compared with sygeneic BMT recipients. Whereas 5 control (treated or non-IL-2-treated) animals showed extensive leukemic infiltration of the kidneys, liver, and lungs, neither of 2 recipients of allogeneic cells showed kidney infiltration, and showed little or no infiltration of the liver or lungs. It is clear that recipients of 2B-4-2 and allogeneic spleen cells died of their leukemia in this experiment because nonleukemic controls showed 100% survival in the same time period. Although the exact morbid event is not known, these leukemic recipients of allogeneic T cells may have died from hematopoietic complications of their leukemia, which would not necessarily have been associated with extensive tissue infiltrates.
In contrast to the pronounced GVL effect of allogeneic BMC/spleen cell administration, host-type (BALB/c) spleen cells did not prolong survival in leukemic BALB/c recipients of lethal irradiation, syngeneic BMT and IL-2 treatment. We compared survival in 2B-4-2-treated, irradiated recipients of syngeneic BMC only, syngeneic BMC plus syngeneic spleen cells, or TCD syngeneic BMC, plus allogeneic (B10) BMC and spleen cells. Similar numbers of untreated B10 or BALBIc spleen cells were given to the indicated groups, and all animals received IL-2 treatment. Median survival time (MST) was 23 days, 19 days, and 32 days, respectively, indicating that allogeneic cells were required for the GVL effect in L-2-treated mice.
B10 CD4' and CD8' T cells mediate GVL effects in IL-2-treated mice. We next wished to determine which cell types were responsible for the GVL effect of B10 spleen cell inocula. We compared the magnitude of the GVL effect in lethally irradiated leukemic BALB/c recipients of TCD-BALB/c BMC and TCD-B10 BMC, along with B10 spleen cells that were treated with C alone, or that were depleted of CD4', CD8', or both T-cell subsets with specific MoAb and C. Similar results were obtained in two of two experiments, one of which is shown in Fig 3. Once again, survival was significantly prolonged by administration of undepleted B10 spleen cells compared with controls ( P < .005). This prolongation was partly, but not completely, diminished by depletion of either CD4' or CD8' T cells from the inoculum ( P < .005 comparing recipients of CDCdepleted or CD8-depleted B10 spleen cells with recipients of no B10 spleen cells). Depletion of both T-cell subsets, on the other hand, led to complete abrogation of the GVL effect of B 10 spleen cells, so that survival was indistinguishable from that of animals receiving BMC alone ( P = .75; P < .01 comparing recipients of CD4-and CD8-depleted spleen cells with recipients of spleen cells depleted of either CD4+ or CD8' cells). Fluorescence-activated cell sorter (FACS) analyses showed that depletion of each subset was 94% to 99.5% complete. In addition, the complete loss of GVL effects in recipients of B 10 spleen cell inocula depleted of both subsets indicates that the failure to see complete abrogation of the GVL effect with depletion of any one subset was not simply due to incomplete depletion. Thus, both CD4' and CD8+ T cells mediate a GVL effect in IL-2-treated mice.
Necropsies performed on 6 of 8 leukemic animals receiving only BMC showed marked splenic enlargement; similar enlargement was seen in 8 of 11 leukemic mice receiving BMC with B10 spleen cells depleted of CD4+ and CD8+ cells. In contrast, 0 of 11 animals receiving C-treated control B10 spleen cells showed splenic enlargement at death; 0 of 12 recipients of CD4-depleted and 5 of 13 recipients of CD8-depleted B10 spleen cells showed marked splenic enlargement.
As shown in Fig 3B, IL-2 inhibited GVHD mortality in nonleukemic controls receiving both CD4' and CD8+ T cells in the same experiment. Because all of the animals in the top panel of Fig 3 were IL-2 -treated, this experiment shows that IL-2 can inhibit GVHD while preserving GVL effects of both CD4' and CD8+ T cells.
The magnitude of CD4-mediated and CD8-mediated GVL effects is not reduced by IL-2 treatment. Our next studies were performed to determine whether or not IL-2 inhibited the magnitude of the GVL effect of either CD4' or CD8+ .001 for either group of recipients of CD4-depleted spleen cells compared with recipients of marrow only; P = .95 comparing control and L-2-treated recipients of CD4-depleted spleen cells) of B10 CD8' cells. Because control animals not receiving tumor showed very little GVHD mortality, and IL-2 had no effect on survival of such controls (Fig 4B) , it was not difficult to distinguish leukemic mortality from GVHD mortality in tumor recipients in this experiment.
We next evaluated the possible effect of IL-2 on the magnitude of the GVL effect of B10 CD4+ cells in this model. This experiment was more difficult to perform, as CD4+ cells can cause GVHD in the absence of CD8+ cells in this strain c~mbination,'~ making it difficult to distinguish GVHD mortality from leukemic mortality in animals not receiving IL-2 treatment. However, by comparison with nonleukemic controls, we were able to show that the magnitude of the GVL effect (which was small in the two experiments performed that are combined in Fig 5) of B10 CD4+ cells was not reduced by treatment with IL-2. The GVL effect achieved statistical significance in IL-2-treated mice ( P < .05 comparing IL-2-treated leukemic recipients of CD8-depleted B10 spleen cells to leukemic recipients of BMC only). However, statistically significant survival prolongation was not observed in the non-11-2-treated recipients of CD8-depleted B10 spleen cells ( P = .15), most likely because several early GVHD-related mortalities were observed in this group. We believe these early (< 10 days) mortalities were GVHD-induced, because similar early mortality was observed for the nonleukemic GVHD controls receiving similar treatment (Fig 5B) . In contrast, no early mortalities were observed in IL-2-treated nonleukemic control recipients of B10 CD4+ cells (Fig 5B) or in IL-2-treated leukemic recipients of these cells (Fig 5A) , allowing detection of a statistically significant GVL effect.
Chimerism in long-term survivors. Peripheral WBC chimerism was evaluated in long-term surviving animals in three separate experiments. One control and one IL-2-treated nonleukemic recipient of B 10 spleen cells plus TCD syngeneic and allogeneic BMC in which peripheral WBC were phenotyped 122 days post-BMT showed complete (>99%) donor-type hematopoietic reconstitution. Among animals typed at 177 and 293 days post-BMT, leukemic (n and granulocytes and 99% of monocytes of an animal that received TCD-B10 BMC alone without spleen cells. Three of five control recipients of TCD B10 plus TCD-BALB/c marrow without B10 spleen cells showed mixed chimerism in all lineages, whereas the remaining two mice repopulated only with host-type WBC.
DISCUSSION
In this study, we have developed a new transplantable acute myelogenous leukemia model to show that the GVL effect of both CD4' and CD8+ T cells is completely preserved in BMT recipients treated with a short course of highdose L 2 that inhibits CD4-dependent GVHD. This is, to our knowledge, the first in vivo demonstration that the GVL effect and GVHD-producing capacity of unprimed bulk Tcell populations consisting of a single subset (ie, CD4') can be dissociated. This result suggests a novel mechanism by which GVHD might be avoided while GVL effects of alloreactive donor T cells could be exploited for their GVL effects in HLA-mismatched clinical BMT.
Because a virally-induced tumor was used for our studies, reactivity directed against tumor-associated antigens could have been present. However, host-type T cells administered in BALBk spleen cell inocula did not mediate a detectable antileukemic effect in IL-2-treated BMT mice. Host-restricted T cells educated in a host thymus were administered in these syngeneic spleen cell inocula, and should have been able to optimally recognize virus-specific peptides presented on the host-type 2B-4-2 leukemia cells. In contrast, donor T cells in allogeneic spleen cell inocula are educated in a donor thymus, and therefore, recognize peptide antigen in the context of donor MHC. Therefore we believe that viral peptide-specific reactivity on its own cannot explain the GVL effect of allogeneic CD4' or CD8+ T cells, and that the majority of this GVL effect is caused by alloreactivity. However, we cannot rule out the possibility that interactions 
TIME (DAYS)
m between virus-specific and alloreactive T cells could explain the greater GVL effect of allogeneic T cells. In addition, it is possible that the use of a less rapidly lethal leukemia model would permit less potent responses directed against virus-specific antigens to mediate a detectable GVL effect. However, our use of a rapidly lethal leukemia established in recipients 1 week before irradiation and BMT permits detection of only the most potent antileukemic activity, such as that caused by recognition of MHC alloantigens. In another leukemia model, we observed antileukemic effects only in the presence of MHC mismatches, and not when MHC-matched allogeneic BMC were given.25 T cells that react against any particular MHC/peptide complex, such as those formed by tumor-associated antigens or minor histocompatibility antigens plus self MHC, are quite rare. In contrast, the frequency of unprimed T cells reacting against allogeneic MHC antigens is several orders of magnitude higher than that directed against even multiple minor histocompatibility antigens plus "self" MHC. Therefore, more potent antileukemic effects would be expected in MHC-mismatched BMT, as we have observed." Whereas antiminor alloreactivity clearly mediates antileukemic effects in human BMT, it is likely that more potent GVL effects would be achieved if BMT could be performed safely across wider HLA disparities. Indeed, lower leukemic relapse rates have been observed for related or unrelated single HLA antigenmismatched BMT recipients than for HLA-identical transplants.'" Unfortunately, these improved GVL effects are mitigated by increased GVHD, resulting in no survival advantage compared with HLA-matched transplants.'"
The results reported here suggest a method of attenuating the GVHD-producing activity of allogeneic CD4' T cells while preserving the GVL effects of the same T-cell subset in HLA-mismatched transplantation. With a few exceptions?6 CD4+ cells have been found to play a critical role in inducing acute GVHD across complete MHC barriers in ~ce.12,13.27- 31 We have shown CD4 dependence for acute GVHD in the B 10 "* BALBk strain combination used here." Similar CD4 dependence of full haplotype-mismatched GVHD has been observed in preliminary studies in miniature swine (T. Sablinski and D.H. Sachs, unpublished data, September 1992). Thus, in most cases, inhibition of CD4 functions with IL-2 could reduce GVHD without diminishing CD8-mediated GVL effects, as we have previously shown for the EL4 1eukemiaAymphoma in the N J + B10 strain combination.'* We have shown that CDCdependent GVHD can be inhibited by IL-2 in several fully MHC-mismatched strain combinations. In addition, when CD4+ cells were given without CD8+ cells in the NJ "* BIOLZ or in the B10 "* BALB/c c~mbination,'~ IL-2 inhibited GVHD. However, before this information can be optimally utilized in HLA-mismatched clinical BMT, it will be necessary to gain a clearer understanding of the factors that determine CD4 dependence of GVHD, of which CD4 activities mediate GVHD (and GVL), and of which of these activities are inhibited by IL-2. Therefore, an alternative approach to preserving GVL effects while inhibiting GVHD might involve selective CD4 depletion of allogeneic inocula. However, this latter approach has several potential disadvantages compared with IL-2 treatment: (1) preliminary studies in a miniature swine full haplotype-mismatched BMT model suggest that CD4 depletion eliminates GVHD, but also leads to a high incidence of failure of engraftment (T. Sablinski and D.H. Sachs, unpublished data), suggesting an important role for CD4+ cells in promoting alloengraftment in large animals. IL-2 treatment has been shown not to inhibit the engraftmentpromoting effects of allogeneic T cells in mice," (2) CD4 depletion would remove CD4-mediated GVL effects. CD4+ T cells have been shown to participate in GVL reactions in For personal use only. on November 11, 2017. by guest www.bloodjournal.org From
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another model3* besides the one reported here. In contrast to results in pan-T-cell-depleted BMT, clinical GVHD can be reduced whereas GVL is apparently preserved when CD8+ T cells are depleted from HLA-matched sibling marrow,33*34 suggesting that CD4' T cells may also mediate GVL effects in man. This is not surprising, because many human leukemias express class I1 MHC antigens. The susceptibility of the 2B-4-2 leukemia and the lack of susceptibility of EL4 to CD4-mediated GVL effects" probably reflects the expression on 2B-4-2, but not on Em, of class I1 MHC antigens (M. Sykes, D.A. Pearson, M.W. Harty, unpublished data, September 1991). Therefore, L -2 treatment might provide a superior approach compared with selective CD4 depletion of allogeneic marrow because of its potential to better preserve alloengraftment and GVL effects while avoiding GVHD in class I1 MHC-mismatched BMT.
In addition to the current result showing preservation of CD4-mediated GVL effects while CDCmediated GVHD is inhibited in IL-2-treated mice, several other lines of evidence support the conclusion that not all CDCmediated activities are inhibited by IL-2: (1) More complete inhibition of GVHD was observed in non-L-2-treated recipients of CD4-depleted allogeneic spleen cells than in L-2-treated recipients of undepleted spleen cells from the same allogeneic donors in this B10 --P BALBk strain combination. Indeed, we have observed that IL-2 does not inhibit CD4-mediated chronic GVHD in this c~mbination.'~ Thus, not all GVHD-producing CD4 activity is inhibited by L -2 treatment; (2) In an MHC-matched, multiple minor antigen disparate strain combination, B 10 + C3H.SW, CD4+ T cells made a small contribution to GVHD, but L -2 provided no GVHD protection, suggesting that the CD4-mediated component of GVHD in this strain combination was qualitatively distinct from the L-2-sensitive CD4 functions that cause GVHD across MHC barrier^'^; (3) In 1 of 10 fully MHC-mismatched strain combinations examined, B 10 "* AfJ, L -2 did not provide any protection against GVHD, which was CD4-dependent.I3 Together, these results suggest that there are qualitative (not only quantitative) differences in the CD4 activities that mediate GVHD in the various strain combinations, and that some, but not all of these activities, are inhibited by IL-2. Fortunately, the CD4 activities leading to GVL effects, at least in the 2B-4-2 model, are not susceptible to inhibition What are the CD4 cell functions or subsets that are sensitive or resistant to the inhibitory effects of L-2? CD4+ T cells can contribute to GVHD through both helper and cytolytic a~tivities,~'.~~ and helper activities include several &S-tinct patterns of cytokine p r o d~c t i o n .~~.~~ Preliminary in vitro and in vivo studies suggest that IL-2 perturbs Thl activity, may increase Th2 activity, and does not inhibit cytolytic activity of CD4+ T cells (M. Sykes, J, Szebeni, M. Wang, unpublished data, January 1994). In vitro studies showed that Thl and not Th2 CD4+ clones can be prevented from responding to antigen if they are first exposed to IL-2.39 Therefore, we hypothesize that the GVL effect of B 10 CD4+ cells against 2B-4-2 is caused by cytolytic activity, and that Thl functions do not contribute to GVL, but play an essential by IL-2. role in producing GVHD. Indeed, the Thl-associated cytokines interferon y and IL-2 have been implicated as important mediators of GVHD p a t h o p h y~i o l o g y .~~~ Studies are in progress to determine the precise role of IL-2-induced alterations in CD4 function in GVHD inhibition, and to determine the non-11-2-sensitive CD4 functions that mediate GVL effects.
Previous studies described in the experimental and clinical literature have shown that GVHD and GVL effects of T cells can be d i s~o c i a t e d .~'~ Several mechanisms have been proposed to explain this dissociation, including the recognition of tumor-associated or tissue-specific antigen^.^^^^^"^ However, this study is the first, to our knowledge, to suggest that recognition of MHC alloantigens by unprimed bulk Tcell populations consisting of a single subset can be associated with separable GVHD-producing and GVL activities. A better understanding of this dichotomy might permit the performance of HLA-mismatched BMT to maximize donor availability and both CD4-mediated and CD8-mediated GVL effects while minimizing GVHD. For personal use only. on November 11, 2017. by guest www.bloodjournal.org From
